drugset / Trial / NCT03769285
Skin Cancer Prevention With Nicotinamide in Transplant Recipients - Pilot Trial
Phase 2
Unknown
120 enrolled
Women's College Hospital
Canadian Institutes of Health Research (CIHR) · collabNOW Foods · collabNatural Life Nutrition · collabThe Kidney Foundation of Canada · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
A common long-term side effect of anti-rejection (immunosuppressant) medications is skin cancer. This pilot clinical trial evaluates the feasibility of conducting a larger pivotal trial to examine the efficacy and safety of nicotinamide for prevention of keratinocyte carcinoma in solid organ transplant recipients. This pilot trial will transition into the pivotal trial if all feasibility targets are met.
Timeline
- Start
- 2018-12-03
- Primary completion
- 2023-12
- Completion
- 2023-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nicotinamide | Other / unclassified | 500 mg | Oral |